eyeforpharma
First Name
Last Name
Email Address*
Country
Business Type*

Real World ReportAn in-depth breakdown of the data sources that provide you the evidence needed to prove value in the ‘real world’

The new market access environment is value-driven. With shrinking health budgets – the drug budget is being more heavily scrutinised than ever before. To guarantee access, payers and HTA agencies need to know exactly what medicines will do in the ‘real world’ – EVEN with orphan drugs where small patient populations make evidence hard to come by. That's why eyeforpharma have commissioned the exclusive whitepaper Real World Data: Sources & Applications

Fill in your details on the right to get the Real World Data Whitepaper sent straight to your inbox

Taken from interviews and in-depth insights from senior thought leaders from Janssen, Amgen, CPRD, UBC and the author of ‘The Future of Health Economics’ you will gain an understanding of:

  • The best sources of real world data for late-phase trials, product strategy and clinical decision-making
  • The benefits and limitations of data sources used for evidence generation
  • The disruption real world data will cause to R&D, clinical outcomes and market access

Fill in your details on the right to get the whitepaper sent straight to your inbox

Would love to know what you think of it.

Paul

Paul Simms
Chairman
eyeforpharma
psimms@eyeforpharma.com